ASX:CSLBiotechs
Did CSL's US$1.5 Billion US Plasma Build-Out Just Shift CSL's (ASX:CSL) Investment Narrative?
CSL has recently broken ground on a US$1.50 billion expansion of its Kankakee, Illinois plasma-therapy manufacturing facility, adding at least 300 new pharmaceutical jobs and incorporating its patented Horizon 2 process to increase immunoglobulin and albumin production capacity by 2031.
This large-scale build-out not only deepens CSL’s U.S. manufacturing footprint but also advances its goal of end-to-end plasma processing within the United States, which may be important for supply resilience...